T-bet expressing B cells - Novel target for autoimmune therapies?

Anatoly V Rubtsov; Philippa Marrack; Kira Rubtsova

doi:10.1016/j.cellimm.2017.04.011

T-bet expressing B cells - Novel target for autoimmune therapies?

Cell Immunol. 2017 Nov:321:35-39. doi: 10.1016/j.cellimm.2017.04.011. Epub 2017 May 23.

Authors

Anatoly V Rubtsov¹, Philippa Marrack², Kira Rubtsova³

Affiliations

¹ Howard Hughes Medical Institute, Denver, CO 80206, USA; Department of Biomedical Science, National Jewish Health and Department of Immunology and Microbiology, University of Colorado Health Sciences Center, Denver, CO 80206, USA.
² Howard Hughes Medical Institute, Denver, CO 80206, USA; Department of Biomedical Science, National Jewish Health and Department of Immunology and Microbiology, University of Colorado Health Sciences Center, Denver, CO 80206, USA; Department of Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA; Department of Biochemistry and Molecular Genetics, University of Colorado Health Sciences Center, Aurora, CO 80045, USA.
³ Howard Hughes Medical Institute, Denver, CO 80206, USA; Department of Biomedical Science, National Jewish Health and Department of Immunology and Microbiology, University of Colorado Health Sciences Center, Denver, CO 80206, USA. Electronic address: rubtsovak@njhealth.org.

PMID: 28641866
DOI: 10.1016/j.cellimm.2017.04.011

Abstract

Autoimmune diseases affect more than 23.5million Americans. Traditional therapies for autoimmune diseases involve immunosuppressive drugs that globally dampen immune responses or target and kill large populations of normal immune cells. Both approaches lead to severe dysfunction of the immune system increasing the risk of infections and cancer. Therefore, a more targeted approach, modulating only the pathogenic autoimmune response, would be tremendously beneficial for autoimmune patients. However, only some novel targets involved in pathogenic autoimmune response have been discovered and it is likely that more remain, currently unknown. Here we review the data that have recently been described about T-bet+ B cells (also known as ABCs). Some data suggest that this B cell subset includes cells that are pathogenic in autoimmune responses. Therefore procedures that target these cells might be useful in autoimmune therapies.

Keywords: Autoimmunity; B cells; T-bet.

Publication types

Review

MeSH terms

Animals
Autoimmune Diseases / immunology*
Autoimmune Diseases / therapy*
B-Lymphocyte Subsets / immunology
B-Lymphocyte Subsets / metabolism
B-Lymphocytes / immunology*
B-Lymphocytes / metabolism
Encephalomyelitis, Autoimmune, Experimental / immunology
Encephalomyelitis, Autoimmune, Experimental / therapy
Humans
Models, Immunological
Molecular Targeted Therapy / methods
Molecular Targeted Therapy / trends
T-Box Domain Proteins / genetics
T-Box Domain Proteins / immunology*
T-Box Domain Proteins / metabolism

Substances

T-Box Domain Proteins
T-box transcription factor TBX21